Monitoring Cardiac Symptoms? HeartBeam Extends Pact With Samsung For LIVMOR Solutions

HeartBeam, Inc. BEAT shares are trading higher after entering a strategic alliance agreement with Samsung Electronics Co Ltd SSNGY SSNLF.
The deal extends the existing pact between HeartBeam's recently-acquired LIVMOR and Samsung. The financial terms were not disclosed.
Under the latest deal, HeartBeam and Samsung will assess and monitor cardiac symptoms, tapping the HeartBeam's patented technology.
"Our newly acquired state of the art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo™ telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting," said Branislav Vajdic, Ph.D., HeartBeam CEO and Founder.
HeartBeam acquired the assets of LIVMOR earlier this year. Founded in 2016, LIVMOR developed the Halo Atrial Fibrillation (AF) Detection System, the world's first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring.
The potential of combining LIVMOR's technology and the HeartBeam AIMIGo system holds significant promise to address primary cardiac conditions for veterans.
Price Action: BEAT shares are trading higher by 7.6% to $2.34 on the last check Tuesday.